Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Lanreotide (Somatuline Depot)8 residuesCVYWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Somatuline Depot, Somatuline Autogel, BIM-23014
The CLARINET trial cut tumor progression risk by 53% in patients with gastroenteropancreatic neuroendocrine tumors. Lanreotide (brand name Somatuline Depot) is a synthetic somatostatin analog, an eight-amino-acid cyclic peptide that mimics the body's own growth hormone brake. It earned FDA approval for acromegaly in 2007 and for GEP-NETs in 2014. One deep subcutaneous injection every 28 days from a pre-filled syringe replaces what used to require daily shots. The trade-off is real: diarrhea hits 35 to 65% of patients early on, and gallstones develop in roughly one in four long-term users. Endocrinologists and oncologists prescribe it when pituitary tumors overproduce growth hormone or when neuroendocrine tumors need slowing down.
A 53% reduction in tumor progression risk. That single number from the CLARINET trial (204 patients with GEP-NETs)[1] turned lanreotide into a cornerstone of neuroendocrine tumor management. Lanreotide (Somatuline Depot, CAS 108736-35-2) is a cyclic octapeptide analog of somatostatin. It binds somatostatin receptor subtypes SST2 and SST5 with high and moderate affinity, respectively. That receptor activation does two things: it shuts down excess growth hormone and IGF-1 secretion from pituitary somatotrophs, and it triggers antiproliferative signaling in neuroendocrine tumor cells. The depot formulation uses a supersaturated poloxamer gel that forms a slow-release deposit at the injection site, maintaining therapeutic drug levels for a full 28-day cycle. In practice, most patients fall into two camps. Acromegaly patients receive 90 mg every 28 days as a starting dose, titrated between 60 and 120 mg based on GH and IGF-1 levels. The PRIMARYS trial [2] tracked 90 treatment-naive acromegaly patients and found 63% achieved at least 20% pituitary tumor shrinkage by week 48. GEP-NET patients receive a fixed 120 mg every 28 days. CLARINET showed median progression-free survival of 32.8 months versus 18.0 months on placebo. The 2025 STARTER-NET trial added a new wrinkle: combining lanreotide with everolimus pushed median PFS from 13.6 to 29.7 months in higher-risk GEP-NETs (HR 0.44, p=0.00016). A generic version from Cipla received FDA approval in May 2024, bringing costs down from about $4,200 to roughly $2,435 per 120 mg injection. Side effects are front-loaded; diarrhea and abdominal pain hit hardest in the first few months, and long-term gallstone monitoring is non-negotiable.
Somatostatin is the body's built-in hormone brake. It circulates briefly, with a half-life under three minutes, then gets cleared. Lanreotide copies that molecule's receptor-binding structure but locks it into a cyclic octapeptide that persists for weeks instead of seconds. The primary target is somatostatin receptor subtype 2 (SST2). When lanreotide binds SST2 on pituitary somatotroph cells, it inhibits adenylyl cyclase. Intracellular cAMP drops. Growth hormone secretion slows. Downstream, IGF-1 production in the liver follows GH levels downward. SST2 activation also engages tyrosine phosphatase pathways that carry separate antiproliferative effects on tumor cells. A secondary target, SST5, gets moderate-affinity binding. SST5 activation reduces intracellular calcium, adding another layer of hormone suppression and cell proliferation control. Activity at SST1, SST3, and SST4 is minimal. The depot formulation is what makes monthly dosing work. Lanreotide sits in a supersaturated solution that, once injected deep subcutaneously, forms a gel deposit at the site. Drug releases slowly from that gel over 28 days. Peak serum concentration hits within the first 24 hours; levels stay above 1 ng/mL through the entire dosing interval. True pharmacokinetic steady state builds over 4 to 5 injections. In neuroendocrine tumors, the combined SST2 and SST5 actions suppress tumor-derived hormone release (reducing carcinoid syndrome symptoms like flushing and diarrhea) while simultaneously slowing tumor cell division.
FDA-approved for acromegaly and GEP-NETs with strong Phase III evidence. Normalizes GH/IGF-1 in 39-70% of acromegaly patients; reduces GEP-NET progression risk by 53% (CLARINET). 2025 Phase III (STARTER-NET) established everolimus + lanreotide as emerging first-line doublet for G1/G2 GEP-NETs with adverse features.
CLARINET (NEJM 2014, PMID 25014687): mPFS 32.8 vs 18.0 months, 53% risk reduction; PRIMARYS (JCEM 2014, PMID 24423301): 63% of acromegaly patients achieved ≥20% pituitary tumor shrinkage at 48 weeks; STARTER-NET (ASCO GI 2025): everolimus+lanreotide mPFS 29.7 vs 13.6 months (HR 0.44, p=0.00016)
Long-term gallstone risk 20-33% (requires annual ultrasound monitoring). Glycemic destabilization in diabetics. No head-to-head RCT vs octreotide LAR for superiority in acromegaly (SWITCH trial ongoing). Antibody formation in ~7% reduces long-term efficacy. High cost (~$2,400-4,600/injection) limits access without insurance.
Exclusively used in clinical settings for acromegaly and GEP-NETs. No biohacking or wellness community adoption. Patient-reported outcomes in disease forums broadly align with clinical trial data. GI side effects and injection site reactions are the dominant tolerability complaints. Monthly injection schedule is strongly preferred over daily/weekly alternatives.
Lanreotide is used exclusively in supervised clinical practice for serious medical conditions (acromegaly, GEP-NETs, carcinoid syndrome). No biohacking, performance-enhancement, or wellness community use identified. Community-reported experience reflects patient experience with FDA-approved indications only: no divergent dosing approaches or community-discovered protocols.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 60mg | Monthly |
| Moderate | 90mg | Monthly |
| Aggressive | 120mg | Monthly |
Lanreotide is different from most peptides on this platform. There is no vial to reconstitute, no bacteriostatic water, no insulin syringe math. It arrives as a pre-filled syringe in three strengths: 60 mg (0.3 mL), 90 mg (0.3 mL), and 120 mg (0.5 mL). You inject the full contents. That's it. The catch is that this is a deep subcutaneous injection into the upper outer quadrant of the buttock, not a typical belly or thigh pinch. Many patients have a healthcare provider do it, at least initially. Cold chain matters. Store at 2 to 8 degrees Celsius. Pull the syringe out 30 minutes before injection to reach room temperature; cold gel is thicker and harder to push through the needle. One thing beginners miss: GI side effects in the first month are not a sign that something went wrong. They are expected. Low-fat meals (under 40 g/day) and pancreatic enzyme supplements help considerably. Alternate left and right buttock each month. Superficial injection worsens nodule formation.
Lanreotide is used continuously as long as clinical benefit is maintained. For acromegaly, it is typically a lifelong treatment unless surgery or radiation achieves remission. For GEP-NETs, treatment continues until disease progression or unacceptable toxicity. Dose adjustments are made based on GH/IGF-1 levels (acromegaly) or tumor response (GEP-NETs).
Lanreotide has no off-cycle: it is continuous, indefinite therapy for chronic medical conditions. The "cycling" paradigm does not apply: treatment continues until disease remission (achieved surgically or via radiation, rarely), disease progression, or unacceptable toxicity. The continuous dosing structure is sustained by ongoing monitoring: serial GH/IGF-1 levels drive dose adjustments in acromegaly; imaging and tumor markers define continuation in GEP-NETs. Approximately 7% of patients develop anti-lanreotide antibodies that cause gradual loss of biochemical control over years of therapy, detectable through serial IGF-1 monitoring.
Or use the universal Peptide Calculator for any peptide.
Expected: 39-70% GH/IGF-1 normalization at 3-6 months; 63% pituitary tumor volume reduction ≥20% by 48 weeks (PRIMARYS trial)
Monitor: GH random (target <1 ng/mL), IGF-1 age/sex-adjusted, gallbladder ultrasound (baseline then annually), fasting glucose, TSH, blood pressure, resting heart rate
Remove the pre-filled syringe from the refrigerator and let it sit at room temperature for 30 minutes. Do not microwave or use hot water to warm it.
Choose the upper outer quadrant of one buttock (alternate sides each month).
Clean the injection site with an alcohol swab and let it dry.
Do not prime or expel any air; the syringe is ready to use as-is.
Insert the needle at a 90-degree angle, rapidly, to its full depth. This is a deep subcutaneous injection.
The gel is viscous, especially the 120 mg (0.5 mL) syringe. Expect it to take 10 to 20 seconds.
Do not rub the injection site afterward; gentle pressure with gauze is fine.
Dispose of the syringe in a sharps container immediately.
The three syringe strengths: 60 mg in 0.3 mL, 90 mg in 0.3 mL, 120 mg in 0.5 mL. There is no dose adjustment by volume; you always inject the full syringe.
Mark your calendar. Consistency in the 28-day cycle keeps serum levels in the therapeutic range.
STARTER-NET Phase III (ASCO GI 2025): lanreotide 120mg q28d + everolimus 10mg daily improved mPFS from 13.6 to 29.7 months (HR 0.44, p=0.00016) vs everolimus alone in G1/G2 GEP-NETs with poor prognostic features (Ki-67 5-20% or diffuse liver metastases). Synergistic antiproliferative: SSA suppresses GH/IGF-1 → reduces mTOR input; everolimus directly inhibits mTORC1.
Lanreotide 120mg q28d + everolimus 10mg orally daily. Dose reduce/hold everolimus for grade ≥2 mucositis, hyperglycemia, or pneumonitis. Grade 3+ toxicity rate 35.6%: requires active management.
Off-label combination for acromegaly with partial GH/IGF-1 control on SSA monotherapy. Meta-analyses show 30-40% additional IGF-1 normalization rate with combined SSA + cabergoline vs SSA alone. Cost-effective add-on step before escalating to pegvisomant.
Cabergoline 0.5-2mg twice weekly added to lanreotide in acromegaly patients with IGF-1 1.0-1.5x ULN despite 90-120mg lanreotide q28d.
GH receptor antagonist for acromegaly refractory to SSA alone. Combination with lanreotide allows lower pegvisomant doses with maintained IGF-1 normalization while preserving SSA antiproliferative effect on pituitary tumor. Used in ~15% of acromegaly patients at specialized centers.
Lanreotide 90-120mg q28d + pegvisomant 10-20mg daily SC (adjusted monthly by IGF-1). Requires monthly liver function monitoring (hepatotoxicity risk).
Somatostatin analogs compete with Lutathera for SSTR binding at tumor sites, reducing PRRT uptake and efficacy. FDA label mandates discontinuing lanreotide 4-6 weeks before each Lutathera dose. Can resume lanreotide as SSA backbone maintenance between PRRT cycles.
Do not combineLanreotide reduces cyclosporine bioavailability (altered GI motility + possible CYP3A4 modulation). Clinically significant interaction: cyclosporine blood levels may fall below therapeutic range. Monitor trough levels closely and adjust cyclosporine dose.
Lanreotide suppresses both insulin and glucagon secretion, unpredictably shifting glycemic balance. Net effect depends on indication and baseline. Diabetics may experience either hypoglycemia or hyperglycemia after dose initiation or change. Frequent monitoring and dose adjustment required.
Lanreotide slows resting heart rate via sinus node modulation. Additive bradycardia with concurrent HR-reducing agents. Obtain baseline ECG; monitor resting HR. Clinically significant if resting HR falls <50 bpm or conduction abnormality develops.
Pricing updated 2026-04-09
Gallstones. That is the side effect that separates lanreotide from most other peptide therapies. Somatostatin analogs reduce gallbladder contractility, and over time, bile stasis leads to stone formation in 20 to 33% of long-term users. Most stones are asymptomatic. A subset will need cholecystectomy. Annual gallbladder ultrasound is not optional; it is part of every prescribing guideline for this drug. Diarrhea affects 35 to 65% of patients and is the most common early complaint. It hits hardest in the first one to three injections. The mechanism is fat malabsorption: somatostatin analogs suppress pancreatic lipase secretion, so dietary fat passes through undigested. Restricting fat intake to under 40 grams per day and adding oral pancreatic enzyme supplementation helps most patients. By month three, the majority have adapted. Abdominal pain (34%) and nausea/vomiting (19%) follow the same early-onset, dose-dependent pattern. These GI effects are the leading reason patients ask about discontinuation. Hyperglycemia (14%) is a concern that requires context. Lanreotide suppresses both insulin and glucagon secretion. The net glycemic effect is unpredictable. Some patients run higher; some diabetic patients actually experience hypoglycemia as glucagon drops. Anyone with diabetes needs daily glucose monitoring for at least four weeks after starting or changing dose. Antidiabetic medication adjustments should involve an endocrinologist. Injection site reactions (15%) include pain, induration, and palpable nodules at the buttock injection site. Proper technique matters: full-depth insertion at a 90-degree angle and strict left-right alternation each month reduces nodule formation. Superficial injection makes it worse. Headache (16%), musculoskeletal pain (19%), and hypertension (14%) are all reported at rates worth knowing about. Bradycardia is less common but clinically important. Lanreotide modulates sinus node activity. Resting heart rate can drop below 50 bpm in patients already taking beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. A baseline ECG is standard practice. If resting heart rate falls below 50 or conduction abnormalities appear, the combination needs re-evaluation. Hypothyroidism can develop because somatostatin analogs suppress pituitary TSH secretion. Thyroid function testing every six months catches this early. Depression is reported in about 7% of patients, a number that often gets overlooked in the GI-focused side effect conversation. Antibody formation occurs in roughly 7% of long-term users and can gradually erode biochemical control. Rising IGF-1 levels on a stable dose may be the first sign. Pregnancy is a contraindication. Lanreotide is FDA Category C. Animal data suggests potential fetal harm. Breastfeeding is not recommended because it is unknown whether lanreotide passes into human milk. If diarrhea persists past three months, if gallbladder pain develops, if blood sugar swings become unmanageable, or if resting heart rate drops below 50, contact the prescribing physician. These are signals that need clinical attention, not something to wait out.
Verify Lanreotide (Somatuline Depot) dosing and safety with a second opinion
Lanreotide is a prescription-only pharmaceutical manufactured under GMP conditions. AB-rated generic (Cipla, FDA final approval May 2024) is available alongside brand Somatuline Depot (Ipsen). No meaningful compounding or underground market exists: the depot formulation (poloxamer-based gel at specific pH for 28-day sustained release, cold-chain required) cannot be practically replicated from raw peptide. Research-grade lanreotide powder is available from peptide vendors but is not bioequivalent to the depot and is cost-prohibitive at therapeutic doses (90-120mg/month would require many mg of raw peptide at $50-500+/mg research pricing).
| Test | When | Target |
|---|---|---|
| GH (random serum) | Baseline, then at months 3, 6, 12, then every 6 months (acromegaly) | <1 ng/mL (random) on SSA therapy; <0.4 ng/mL on oral glucose tolerance test for strict biochemical remission |
| IGF-1 (age- and sex-adjusted) | Baseline, then months 3, 6, 12, every 6 months (acromegaly and GEP-NETs) | Within age/sex-adjusted normal range (laboratory-specific reference) |
| Gallbladder ultrasound | Baseline, then annually | No gallstones; if found, monitor size and symptom development: most are managed conservatively |
| Fasting blood glucose and HbA1c | Baseline, then every 3-6 months (more frequent in diabetics or at dose change) | FBG 70-100 mg/dL (non-diabetic); per individualized diabetes targets in diabetics |
| Thyroid function (TSH, free T4) | Baseline, then every 6 months | TSH 0.4-4.0 mIU/L; free T4 within normal limits |
| Liver function tests (ALT, AST, ALP, bilirubin) | Baseline, then every 6-12 months (monthly if on concurrent pegvisomant or everolimus) | Within normal limits; <3x ULN in oncology combination context (per individual regimen tolerance) |
| Heart rate and ECG | Baseline ECG; monitor HR at each visit; repeat ECG if symptomatic or on concomitant bradycardic drugs | Resting HR >50 bpm; PR interval <200 ms |
| Chromogranin A (CgA) | Baseline, then every 3-6 months (GEP-NETs) | Stable or declining from baseline (laboratory-specific; note proton pump inhibitors elevate CgA: account for this) |
| Cross-sectional imaging (CT or MRI abdomen/pelvis) | Baseline, then every 3-6 months for first year (GEP-NETs); every 6 months if stable | Stable disease or partial/complete response; progressive disease by RECIST triggers treatment change |
Primary efficacy marker for acromegaly; guides dose titration decisions
Integrated GH exposure marker; primary titration endpoint in acromegaly. Also monitoring target in GEP-NETs where IGF-1 axis may be relevant.
Somatostatin analogs reduce gallbladder motility and bile flow, causing 20-33% cumulative cholelithiasis incidence
Lanreotide alters glucose homeostasis by suppressing both insulin and glucagon secretion; net glycemic effect is unpredictable
SSAs can suppress TSH secretion from pituitary and cause subclinical or overt hypothyroidism
Monitor for drug-related hepatotoxicity, especially with combination regimens; also relevant if biliary obstruction from gallstones develops
Lanreotide causes sinus bradycardia; additive risk with beta-blockers, non-dihydropyridine calcium channel blockers, and digoxin
Tumor burden marker for neuroendocrine tumors; rising CgA may precede radiographic progression and can trigger imaging
Assess tumor response and progression per RECIST 1.1 to guide continuation vs switch of therapy
GH levels begin to decline within hours. GI side effects (diarrhea, abdominal pain) are most common during the first few injections. Serum lanreotide concentrations reach therapeutic levels within the first day.
Steady-state drug levels approach with repeated dosing. GH and IGF-1 levels show measurable reduction. GI side effects often improve as the body adapts. Dose titration may be initiated based on GH/IGF-1 response.
Steady-state pharmacokinetics fully established by the 4th-5th injection. Significant IGF-1 normalization expected in responders. Tumor volume reduction detectable on imaging in acromegaly patients. GEP-NET tumor stabilization assessable.
Optimal hormonal control achieved with dose adjustments. PRIMARYS trial showed 63% of patients had ≥20% tumor shrinkage by 48 weeks. Long-term gallbladder monitoring should begin. Symptom improvement in acromegaly (headache, sweating, joint pain).
Continued long-term treatment with periodic monitoring of GH, IGF-1, liver function, glucose, thyroid function, and gallbladder ultrasound. CLARINET trial showed 65% progression-free survival at 24 months for GEP-NETs. Dose extended to every 6-8 weeks in some well-controlled acromegaly patients.
Month 1 (first injection): GH levels start dropping within hours of the first shot. Serum lanreotide hits peak concentration in the first 24 hours and stays above therapeutic levels for the full 28-day interval. Expect diarrhea, abdominal cramps, and flatulence; these are the most common complaints in month one. A palpable nodule at the buttock injection site is normal and not harmful. Nausea affects about 19% of patients during this period. Months 2 to 3: Drug levels approach steady state. GH and IGF-1 show measurable decline. The first biochemical assessment at month 3 (GH plus IGF-1) determines whether your dose needs titration. GI side effects start easing, especially if you have cut dietary fat. Acromegaly patients often notice reduced headaches and less sweating. Plan meals and schedule around injection day; most patients settle into a routine. Months 3 to 6: Full steady-state pharmacokinetics lock in after the 4th or 5th injection. Responders show clear IGF-1 normalization. MRI can detect pituitary tumor volume reduction in acromegaly patients. GEP-NET patients get their first imaging assessment for tumor stabilization. Asymptomatic gallstones may show up on ultrasound. Some patients notice resting heart rate dropping a few beats per minute. Months 6 to 12: PRIMARYS trial data showed 63% of patients with at least 20% pituitary tumor shrinkage by week 48. CLARINET showed 65% progression-free survival at 24 months for GEP-NETs. Dose extension to every 6 to 8 weeks becomes an option for well-controlled acromegaly patients. Long-term gallbladder monitoring kicks in with annual ultrasounds. Patients overwhelmingly prefer the monthly schedule compared to daily injection regimens. Year 1 and beyond: Most patients maintain long-term efficacy on a stable dose. About 7% develop anti-lanreotide antibodies, which cause a gradual creep in IGF-1 levels detectable on serial bloodwork. Some patients sustain disease control for over a decade. The monthly schedule stays well-accepted. A subset will need cholecystectomy for gallstones but can continue lanreotide after surgery. Insurance prior authorization is a recurring frustration that patients mention frequently.
Serum lanreotide reaches Cmax within 24 hours; GH levels begin declining within hours. Therapeutic concentrations (>1 ng/mL) maintained throughout 28-day interval from first dose.
Diarrhea, abdominal cramps, and flatulence are the most frequently reported first-month complaints. Palpable injection site nodule at buttock injection site common; not harmful.
Approaching steady-state drug levels. GH and IGF-1 show measurable reduction. First biochemical assessment (GH, IGF-1) at month 3 guides dose titration decision.
GI side effects begin improving; dietary fat restriction helps most patients. First signs of acromegaly symptom improvement: reduced headache and sweating. Patients often need to modify diet and plan around injection day.
Full steady-state reached after 4th-5th injection. Significant IGF-1 normalization in responders. Pituitary tumor volume reduction detectable on MRI in acromegaly. GEP-NET tumor stabilization assessable by imaging.
Acromegaly patients report ring/shoe size stabilization, reduced joint pain and facial swelling. GEP-NET/carcinoid patients report meaningful reduction in flushing and diarrhea episodes from carcinoid syndrome.
PRIMARYS: 63% of acromegaly patients achieved ≥20% pituitary tumor shrinkage by 48 weeks. CLARINET: 65% PFS at 24 months for GEP-NETs. Dose extension to q6-8 weeks feasible in some well-controlled acromegaly patients.
Long-term tolerability generally good. Annual gallbladder ultrasound findings (gallstones) are a common surprise for patients who feel well. Monthly injection schedule strongly praised vs daily injection regimens.
Continued efficacy maintained in most patients. ~7% develop anti-lanreotide antibodies leading to gradual loss of biochemical control: detectable through rising IGF-1 on stable dose. Some patients achieve sustained disease control for 10+ years.
Monthly dosing schedule remains well-accepted. Patients report significant quality-of-life improvement vs pre-treatment. A subset require cholecystectomy but continue lanreotide post-operatively. Insurance prior authorization battles are a recurrent stressor.
Source: FDA Prescribing Information (Somatuline Depot), Section 12.3: terminal half-life 23 to 30 days for depot formulation
Loading the interactive decay curve.
Lanreotide (Somatuline Depot) holds active FDA approval for two indications: acromegaly (approved 2007) and gastroenteropancreatic neuroendocrine tumors (approved 2014). It is a prescription-only medication. You cannot legally obtain it without a physician's order. The brand product is manufactured by Ipsen. Cipla received final FDA approval for a generic version (AB-rated, all three strengths) on May 22, 2024, and launched the following day. The generic is a verified therapeutic equivalent. Lanreotide does not appear on the WADA Prohibited List. However, any athlete subject to anti-doping testing should confirm current status with their governing body before use. No compounding pharmacy market exists for lanreotide. The depot formulation requires a proprietary poloxamer-based gel manufactured under GMP conditions; it cannot be replicated from raw peptide powder. Research-grade lanreotide is available from peptide vendors but is not bioequivalent to the depot product and would cost $50 to $500 or more per milligram, making therapeutic doses impractical. This content is for informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider for diagnosis and treatment decisions.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
